Triple meeting 2025 – early efficacy signs for Quanta
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
ESMO 2025 – Incyte impresses in KRAS G12D
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
ESMO 2025 preview – Merck hopes for Daiichi redemption
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
ASCO 2025 preview – KRAS challengers assemble
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
